Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 453

1.

Increased mental health care use by mothers of children with multiple sclerosis.

Marrie RA, O'Mahony J, Maxwell C, Ling V, Yeh EA, Arnold DL, Bar-Or A, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2020 Jan 9. pii: 10.1212/WNL.0000000000008871. doi: 10.1212/WNL.0000000000008871. [Epub ahead of print]

PMID:
31919112
2.

Deep learning segmentation of orbital fat to calibrate conventional MRI for longitudinal studies.

Brown RA, Fetco D, Fratila R, Fadda G, Jiang S, Alkhawajah NM, Yeh EA, Banwell B, Bar-Or A, Arnold DL; Canadian Pediatric Demyelinating Disease Network.

Neuroimage. 2020 Mar;208:116442. doi: 10.1016/j.neuroimage.2019.116442. Epub 2019 Dec 9.

3.

Factors associated with health care utilization in pediatric multiple sclerosis.

Marrie RA, O'Mahony J, Maxwell C, Ling V, Till C, Barlow-Krelina E, Yeh EA, Arnold DL, Bar-Or A, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Mult Scler Relat Disord. 2019 Nov 6;38:101511. doi: 10.1016/j.msard.2019.101511. [Epub ahead of print]

PMID:
31722282
4.

Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R.

Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761. [Epub ahead of print]

PMID:
31680631
5.

Exploring uncertainty measures in deep networks for Multiple sclerosis lesion detection and segmentation.

Nair T, Precup D, Arnold DL, Arbel T.

Med Image Anal. 2020 Jan;59:101557. doi: 10.1016/j.media.2019.101557. Epub 2019 Sep 7.

PMID:
31677438
6.

Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes.

Waters P, Fadda G, Woodhall M, O'Mahony J, Brown RA, Castro DA, Longoni G, Irani SR, Sun B, Yeh EA, Marrie RA, Arnold DL, Banwell B, Bar-Or A; Canadian Pediatric Demyelinating Disease Network.

JAMA Neurol. 2019 Sep 23. doi: 10.1001/jamaneurol.2019.2940. [Epub ahead of print]

7.

Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis.

Wilbur C, Reginald YA, Longoni G, Grover SA, Wong AM, Mabbott DJ, Arnold DL, Marrie RA, Bar-Or A, Banwell B, Costello F, Yeh EA; Canadian Pediatric Demyelinating Disease Network.

Mult Scler Relat Disord. 2019 Nov;36:101387. doi: 10.1016/j.msard.2019.101387. Epub 2019 Sep 7.

PMID:
31539739
8.

High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS.

Thebault S, R Tessier D, Lee H, Bowman M, Bar-Or A, Arnold DL, L Atkins H, Tabard-Cossa V, Freedman MS.

Neurol Neuroimmunol Neuroinflamm. 2019 Aug 8;6(5):e598. doi: 10.1212/NXI.0000000000000598. eCollection 2019 Sep.

9.

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.

Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Fecker J, Model F, Wei W, Arnold DL.

Brain. 2019 Sep 1;142(9):2787-2799. doi: 10.1093/brain/awz212.

10.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators.

Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.

PMID:
31492652
11.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators.

Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3.

PMID:
31492651
12.

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators.

Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5.

PMID:
31285147
13.

White matter plasticity and maturation in human cognition.

Bells S, Lefebvre J, Longoni G, Narayanan S, Arnold DL, Yeh EA, Mabbott DJ.

Glia. 2019 Nov;67(11):2020-2037. doi: 10.1002/glia.23661. Epub 2019 Jun 24. Review.

PMID:
31233643
14.

Comparison of Multiple Sclerosis Cortical Lesion Types Detected by Multicontrast 3T and 7T MRI.

Maranzano J, Dadar M, Rudko DA, De Nigris D, Elliott C, Gati JS, Morrow SA, Menon RS, Collins DL, Arnold DL, Narayanan S.

AJNR Am J Neuroradiol. 2019 Jul;40(7):1162-1169. doi: 10.3174/ajnr.A6099. Epub 2019 Jun 20.

PMID:
31221631
15.

High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study.

Marrie RA, O'Mahony J, Maxwell CJ, Ling V, Yeh EA, Arnold DL, Bar-Or A, Banwell B; Canadian Pediatric Demyelinating Disease Network.

PLoS One. 2019 Jun 11;14(6):e0218215. doi: 10.1371/journal.pone.0218215. eCollection 2019.

16.

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.

Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group.

N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10.

PMID:
31075187
17.

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.

Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, Yang L, Fox RJ.

Neurology. 2019 Apr 9;92(15):e1724-e1738. doi: 10.1212/WNL.0000000000007262. Epub 2019 Mar 27.

18.

Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.

Oh J, Ontaneda D, Azevedo C, Klawiter EC, Absinta M, Arnold DL, Bakshi R, Calabresi PA, Crainiceanu C, Dewey B, Freeman L, Gauthier S, Henry R, Inglese M, Kolind S, Li DKB, Mainero C, Menon RS, Nair G, Narayanan S, Nelson F, Pelletier D, Rauscher A, Rooney W, Sati P, Schwartz D, Shinohara RT, Tagge I, Traboulsee A, Wang Y, Yoo Y, Yousry T, Zhang Y, Sicotte NL, Reich DS; North American Imaging in Multiple Sclerosis Cooperative.

Neurology. 2019 Mar 12;92(11):519-533. doi: 10.1212/WNL.0000000000007099. Epub 2019 Feb 20. Review. Erratum in: Neurology. 2019 Jul 2;93(1):46.

PMID:
30787160
19.

Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis.

Mexhitaj I, Nyirenda MH, Li R, O'Mahony J, Rezk A, Rozenberg A, Moore CS, Johnson T, Sadovnick D, Collins DL, Arnold DL, Gran B, Yeh EA, Marrie RA, Banwell B, Bar-Or A.

Brain. 2019 Mar 1;142(3):617-632. doi: 10.1093/brain/awz017.

PMID:
30759186
20.

A surface-in gradient of thalamic damage evolves in pediatric multiple sclerosis.

Fadda G, Brown RA, Magliozzi R, Aubert-Broche B, O'Mahony J, Shinohara RT, Banwell B, Marrie RA, Yeh EA, Collins DL, Arnold DL, Bar-Or A; Canadian Pediatric Demyelinating Disease Network.

Ann Neurol. 2019 Mar;85(3):340-351. doi: 10.1002/ana.25429. Epub 2019 Feb 20.

21.

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.

Elliott C, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Wei W, Belachew S, Arnold DL.

Mult Scler. 2019 Dec;25(14):1915-1925. doi: 10.1177/1352458518814117. Epub 2018 Dec 19.

22.

Pseudomonas syringae: enterprising epiphyte and stealthy parasite.

Arnold DL, Preston GM.

Microbiology. 2019 Mar;165(3):251-253. doi: 10.1099/mic.0.000715. Epub 2018 Nov 14.

PMID:
30427303
23.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2019 Oct;25(12):1605-1617. doi: 10.1177/1352458518796675. Epub 2018 Oct 5.

24.

Incidence and prevalence of MS in children: A population-based study in Ontario, Canada.

Marrie RA, O'Mahony J, Maxwell C, Ling V, Yeh EA, Arnold DL, Bar-Or A, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2018 Oct 23;91(17):e1579-e1590. doi: 10.1212/WNL.0000000000006395. Epub 2018 Sep 26.

PMID:
30258022
25.

Estimating and accounting for the effect of MRI scanner changes on longitudinal whole-brain volume change measurements.

Lee H, Nakamura K, Narayanan S, Brown RA, Arnold DL; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2019 Jan 1;184:555-565. doi: 10.1016/j.neuroimage.2018.09.062. Epub 2018 Sep 22.

PMID:
30253207
26.

Lichen Planus.

Arnold DL, Krishnamurthy K.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-.
2019 Mar 21.

27.

Improving the SIENA performance using BEaST brain extraction.

Nakamura K, Eskildsen SF, Narayanan S, Arnold DL, Collins DL; Alzheimer's Disease Neuroimaging Initiative.

PLoS One. 2018 Sep 20;13(9):e0196945. doi: 10.1371/journal.pone.0196945. eCollection 2018.

28.

Standardized quality metric system for structural brain magnetic resonance images in multi-center neuroimaging study.

Osadebey ME, Pedersen M, Arnold DL, Wendel-Mitoraj KE, Alzheimer's Disease Neuroimaging Initiative FT.

BMC Med Imaging. 2018 Sep 17;18(1):31. doi: 10.1186/s12880-018-0266-4.

29.

Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes.

Longoni G, Brown RA, Aubert-Broche B, Grover SA, Branson HM, Fetco D, Bar-Or A, Marrie RA, Motl RW, Collins DL, Narayanan S, Arnold DL, Banwell B, Yeh EA.

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 6;5(6):e499. doi: 10.1212/NXI.0000000000000499. eCollection 2018 Nov.

30.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

31.

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis.

Arnold DL, Shang S, Dong Q, Meergans M, Naylor ML.

Ther Adv Neurol Disord. 2018 Aug 28;11:1756286418795085. doi: 10.1177/1756286418795085. eCollection 2018.

32.

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN.

Newsome SD, Scott TF, Arnold DL, Nelles G, Hung S, Cui Y, Shang S, Naylor ML, Kremenchutzky M.

Ther Adv Neurol Disord. 2018 Aug 28;11:1756286418791143. doi: 10.1177/1756286418791143. eCollection 2018.

33.

MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study.

Fadda G, Brown RA, Longoni G, Castro DA, O'Mahony J, Verhey LH, Branson HM, Waters P, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Lancet Child Adolesc Health. 2018 Mar;2(3):191-204. doi: 10.1016/S2352-4642(18)30026-9. Epub 2018 Feb 1.

PMID:
30169254
34.

Supercoiling of an excised genomic island represses effector gene expression to prevent activation of host resistance.

Neale HC, Jackson RW, Preston GM, Arnold DL.

Mol Microbiol. 2018 Nov;110(3):444-454. doi: 10.1111/mmi.14111. Epub 2018 Oct 3.

35.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2019 Aug;25(9):1255-1262. doi: 10.1177/1352458518789884. Epub 2018 Jul 25.

36.

Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters.

Osadebey ME, Pedersen M, Arnold DL, Wendel-Mitoraj KE.

Biomed Eng Online. 2018 Jun 13;17(1):76. doi: 10.1186/s12938-018-0514-4.

37.

Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.

Maranzano J, Till C, Assemlal HE, Fonov V, Brown R, Araujo D, O'Mahony J, Yeh EA, Bar-Or A, Marrie RA, Collins L, Banwell B, Arnold DL, Narayanan S.

Mult Scler. 2019 Jun;25(7):980-986. doi: 10.1177/1352458518779952. Epub 2018 Jun 1.

PMID:
29852831
38.

Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial.

Cree BAC, Arnold DL, Cascione M, Fox EJ, Williams IM, Meng X, Schofield L, Tenenbaum N.

Ther Adv Neurol Disord. 2018 May 20;11:1756286418774338. doi: 10.1177/1756286418774338. eCollection 2018.

39.

Coping with Environmental Eukaryotes; Identification of Pseudomonas syringae Genes during the Interaction with Alternative Hosts or Predators.

Dorati F, Barrett GA, Sanchez-Contreras M, Arseneault T, José MS, Studholme DJ, Murillo J, Caballero P, Waterfield NR, Arnold DL, Shaw LJ, Jackson RW.

Microorganisms. 2018 Apr 21;6(2). pii: E32. doi: 10.3390/microorganisms6020032.

40.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170.

PMID:
29576505
41.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

42.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
43.

A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis.

Eisen A, Greenberg BM, Bowen JD, Arnold DL, Caggiano AO.

Mult Scler J Exp Transl Clin. 2017 Nov 21;3(4):2055217317743097. doi: 10.1177/2055217317743097. eCollection 2017 Oct-Dec.

44.

Comment on "Serious infections among a large cohort of subjects with systemically treated psoriasis".

Arnold DL, Feldman SR.

J Am Acad Dermatol. 2018 May;78(5):e113-e114. doi: 10.1016/j.jaad.2017.10.054. Epub 2018 Jan 5. No abstract available.

PMID:
29309819
45.

Hidradenitis and smoking.

Saleem MD, Arnold DL, Feldman SR.

Br J Dermatol. 2018 Mar;178(3):810-811. doi: 10.1111/bjd.16214. Epub 2018 Feb 7. No abstract available.

PMID:
29205268
46.

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.

Kappos L, Arnold DL, Bar-Or A, Camm AJ, Derfuss T, Sprenger T, Davies M, Piotrowska A, Ni P, Harada T.

Mult Scler. 2018 Oct;24(12):1605-1616. doi: 10.1177/1352458517728343. Epub 2017 Sep 15.

47.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

48.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

49.

MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.

Maranzano J, Rudko DA, Nakamura K, Cook S, Cadavid D, Wolansky L, Arnold DL, Narayanan S.

Neurology. 2017 Aug 15;89(7):714-721. doi: 10.1212/WNL.0000000000004227. Epub 2017 Jul 19.

50.

Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.

Arnold DL, You X, Castrillo-Viguera C.

J Neurol. 2017 Aug;264(8):1728-1734. doi: 10.1007/s00415-017-8544-6. Epub 2017 Jul 7.

Supplemental Content

Loading ...
Support Center